Traws Pharma Reports Topline Phase 1 Safety And Pharmacokinetic Results For Investigational One-dose Flu Therapy, Tivoxavir Marboxil; Preclinical Data Showed Potent Inhibition Of Drug-resistant And Bird Influenza Viruses
Portfolio Pulse from Benzinga Newsdesk
Traws Pharma announced positive Phase 1 results for its investigational flu therapy, Tivoxavir Marboxil, showing good tolerability and effective plasma drug levels. The company plans to advance to Phase 2 trials in 2025.
October 08, 2024 | 11:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Traws Pharma's Tivoxavir Marboxil demonstrated positive Phase 1 results, showing good tolerability and effective plasma drug levels for flu treatment. The company plans to proceed to Phase 2 trials in 2025.
The positive Phase 1 results for Tivoxavir Marboxil indicate potential success in future trials, which could lead to a new flu treatment option. This is likely to boost investor confidence and positively impact Traws Pharma's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100